Financial Summary (All financials)
In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
Revenues | 20.2 | 1.6 | 0.0 | 0.0 | 0.1 |
Revenue growth | 1138.8% | | -100.0% | -69.8% | |
Cost of goods sold | 9.3 | 1.6 | -2.4 | 0.0 | 0.0 |
Gross profit | 10.8 | 0.0 | 2.4 | 0.0 | 0.0 |
Gross margin | 53.7% | 1.5% | | 75.0% | 84.9% |
Selling, general and administrative | 73.7 | 63.1 | 21.1 | 8.0 | |
Research and development | 20.9 | 60.4 | 40.7 | 20.2 | 10.2 |
General and administrative | | | | | 4.1 |
EBIT | -83.5 | -122.4 | -59.3 | -26.6 | -13.2 |
EBIT margin | -414.5% | -7521.8% | | -166431.3% | -24964.2% |
Pre-tax income | -91.1 | -125.6 | -60.1 | -26.6 | -13.2 |
Income taxes | 0.1 | 0.5 | 0.0 | 0.0 | 0.0 |
Tax rate | | | 0.0% | 0.0% | 0.0% |
Net income | -91.3 | -126.0 | -60.1 | -26.6 | -13.2 |
Net margin | -452.7% | -7746.7% | | -165962.5% | -24922.6% |
|
Diluted EPS | ($2.14) | ($4.83) | ($4.99) | ($13.09) | ($7.17) |
Shares outstanding (diluted) | 42.6 | 26.1 | 12.0 | 2.0 | 1.8 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|